BRAF and melanoma: The Phase 2 trial of administering them (the NCI-MATCH trial subprotocol H) in patients with certain BRAF-mutated cancers, excluding melanoma and non-small cell lung, thyroid, and colorectal cancers, reported a median progression-free survival (PFS) of 11.4 months and a response rate of 38%.7